CIPRO HC Drug Patent Profile

When do Cipro Hc patents expire, and when can generic versions of Cipro Hc launch?

Cipro Hc is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in CIPRO HC is ciprofloxacin hydrochloride; hydrocortisone. There are thirty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride; hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cipro Hc

A generic version of CIPRO HC was approved as ciprofloxacin hydrochloride; hydrocortisone by COSETTE PHARMS NC on November 10^th, 2025.

Summary for CIPRO HC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CIPRO HC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998	AB	RX	Yes	Yes

International Patents for CIPRO HC

See the table below for patents covering CIPRO HC around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	812032
Cyprus	1301	7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-NAPHTHYRIDINE(-QUINOLINE)-3-CARBOXYLIC ACIDS,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
European Patent Office	0280915

Supplementary Protection Certificates for CIPRO HC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808

CIPRO HC Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Market Position of CIPRO HC?

CIPRO HC (ciprofloxacin and hydrocortisone) is a topical antibiotic combined with a corticosteroid used primarily for bacterial skin infections. It competes in a niche market with a focus on dermatological infections, particularly in the US, Europe, and emerging markets. The formulation targets patients requiring anti-inflammatory and antibacterial therapy, including those with eczema, psoriasis, and other inflammatory skin conditions complicated by bacterial infections.

What Are the Key Market Dynamics and Trends?

The global dermatology drug market is projected to grow from $24.9 billion in 2022 to approximately $37.2 billion by 2030, with a compound annual growth rate (CAGR) of 5.2%[1]. Key drivers include rising incidences of skin infections, increasing prevalence of chronic inflammatory skin conditions, and product innovation. Nonetheless, competition remains intense, primarily from generic formulations and other combination products.

CIPRO HC's market share is limited; it competes with both brand-name and generic topical antibiotics and corticosteroids. Introduction of alternative, non-steroidal anti-inflammatory products, and growing concerns about corticosteroid overuse, could influence demand.

What Are the Regulatory and Patent Fundamentals?

CIPRO HC's patent protection expired in most markets by 2017, enabling generic competition. The original patent, filed circa 2000 and granted in 2002, provided exclusivity until patent expiration. Some formulations or delivery systems may still have market-specific patent protection or exclusivity, but these are generally limited.

Regulatory pathways involve approval by agencies such as the FDA (US), EMA (Europe), and others, based on demonstrated safety and efficacy for topical use. Approval processes for generics require bioequivalence submission, often leading to a sharp price decline for authorized formulations.

What Is the Revenue and Cost Structure?

Sales revenues depend heavily on geographic penetration, with the US accounting for around 65% of sales, based on historical data[2]. Estimated average wholesale price (AWP) for branded CIPRO HC approximates $50 per tube, with generic options priced roughly 50-70% lower.

Manufacturing costs for topical formulations are relatively low, estimated between $2 and $5 per tube, including active ingredients, excipients, and packaging. Distribution costs and marketing contribute significantly, especially for promoting awareness among dermatologists and general practitioners.

What Are the Growth Opportunities and Risks?

Opportunities:

• Expansion into emerging markets where skin infections are prevalent and regulatory barriers are lower.
• Development of novel formulations with improved delivery or fewer side effects.
• Combination therapies addressing resistant bacterial strains.

Risks:

• Patent expiration leading to price erosion.
• Increasing competition from generics and over-the-counter (OTC) medications.
• Regulatory shifts favoring preservative-free or steroid-sparing options.
• Potential for adverse side effects linked to corticosteroid use, reducing prescribing.

How Do Competitive Barriers and Patent Landscapes Affect Investment?

Patent expirations diminish barriers to entry, increasing generic competition and lowering prices. For instance, following patent expiration, branded CIPRO HC sales declined sharply, with market share dispersing among generic suppliers.

Investors must monitor any remaining patent protections on specific formulations or delivery devices. Small-scale patent challenges or regulatory obstacles can influence product lifecycle. Companies that hold orphan or formulation patents may sustain higher margins longer.

What Financial Metrics Are Relevant?

Key metrics include:

• Market penetration rates and growth rates in target regions.
• Pricing power, influenced by patents, formulations, and branded versus generic markets.
• Gross margins, typically 70-80% for branded topical drugs prior to patent expiry.
• R&D expenditure, which is minimal for established formulations, but significant for new indications or delivery methods.

What Are the Implications for Investment?

CIPRO HC's investment outlook depends on patent landscape and market dynamics. Patent expiry has likely led to revenue declines, pushing manufacturers towards pipeline innovations or licensing deals. Entry into emerging markets can offer growth but exposes the product to regulatory volatility.

Key Takeaways

• CIPRO HC is a topical antibiotic/corticosteroid with a limited patent life, resulting in intense generic competition.
• Market growth is driven by rising skin infection rates and prevalence of inflammatory dermatoses.
• Revenue is primarily from the US, with significant decline expected post-patent expiration.
• Opportunities exist in emerging markets and formulation innovations, but risks include price erosion and regulatory shifts.
• Companies maintaining patent protections or developing new formulations may sustain higher margins longer.

Frequently Asked Questions

1. How has patent expiration affected CIPRO HC sales?

Patent expiration around 2017 led to rapid generic entry, causing significant revenue declines for the original branded formulation.

2. What are the key competitors for CIPRO HC?

Generic ciprofloxacin and hydrocortisone formulations, other combination topical antibiotics and steroids, and OTC alternatives.

3. Are there ongoing regulatory challenges?

Yes. Regulatory agencies increasingly scrutinize corticosteroid side effects and promote preservative-free formulations.

4. What markets offer growth potential?

Emerging economies in Asia, Latin America, and Africa present opportunities due to higher prevalence of skin infections and less saturated markets.

5. How can companies extend product lifecycle?

Through patent strategies, development of novel formulations, or exploring new therapeutic indications.

---

Citations

1. Grand View Research, "Dermatology Drugs Market Size, Share & Trends Analysis Report," 2022-2030.
2. IQVIA, "Medicines Use and Spending in the U.S.: A Review of 2022 and Outlook for 2023," 2023. [1] https://www.grandviewresearch.com/industry-analysis/dermatology-drugs-market

[2] https://www.iqvia.com/solutions/reports/medicines-use-and-spending-in-the-u-s